A trusted advisor – Transforming patients’ lives with pioneering molecular diagnostics.

A prognostic and predictive test to guide ER+, HER2-, N0 and N+ breast cancer treatment decisions

A Gene Expression Test
to stratify patients
according to Prostate Cancer

The latest advance in
hereditary Cancer testing

The most comprehensive
HRD tumor test to guide
PARP inhibitor treatment

previous arrow
next arrow

Management Message

Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad discovers and commercializes genetic tests that determine the risk of developing disease, assess the risk of disease progression, and guide treatment decisions across medical specialties where critical genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit the company’s website: www.myriad.com

Read more

Our Mission

Our Products

Myriad offers an array of genetic tests, prognostic tests, and personalized medicine tests to healthcare providers to help them assess a patient’s increased cancer risk, disease aggressiveness, optimize efficacy of chemotherapy and identify patients most suitable for therapy.

Our Pipeline

Myriad possesses the deepest diagnostic pipeline across the disease spectrum, including clinical tests in areas of unmet medical need such as autoimmune diseases, dermatology, neuroscience, oncology, urology and women’s health. Myriad’s research investment totals $358 million over the past five years.

The Science

At Myriad, we use state-of-the art technologies including DNA sequencing, RNA analysis and proteomics to innovate and create the next generation of breakthrough diagnostics.

Our talented scientists are working in collaboration with universities, biotech and pharmaceutical companies, and government agencies to accelerate the pace of innovation for patients worldwide. This approach affords us a diversity of perspectives as well as access to cutting-edge science regardless of where it resides.

Who We Are

31st European Congress of Pathology (ECP)

Myriad is looking forward to meeting you at

the 31st European Congress of Pathology (ECP)
Nice . September 7-11, 2019

Please visit us at booth # R21
and learn more about EndoPredict

44th European Society for Medical Oncology (ESMO)

Myriad is looking forward to meeting you at

44th European Society for Medical Oncology (ESMO)
Barcelona . September 27 – October 1, 2019

PPlease come and visit Myriad’s booth
and learn more about EndoPredict

News Center

  • All
  • Products

Myriad Genetics Receives FDA Approval of BRACAnalysis® CDx as a Companion Diagnostic for Lynparza® in Early Breast Cancer BRACAnalysis CDx is…

Myriad Genetics Receives Additional Reimbursement for myChoice® Diagnostic System in Japan Comprehensive Test Helps Identify Women with Advanced Ovarian Cancer Who…

New Study from Leading University of Utah Radiation Oncologist Validates Ability of Myriad Genetics’ Prolaris® test to Guide Treatment for Prostate…

Myriad Genetics Receives First Reimbursement Decision for myChoice® Diagnostic System in Japan, Enabling Women with Ovarian Cancer to Benefit from Treatment…

Myriad Genetics Announces Global Expansion of Myriad myChoice® Tumor Testing in Europe and China SALT LAKE CITY, Nov. 16, 2020 (GLOBE…

German Federal Joint Committee (G-BA) Issues Nationwide Reimbursement Decision for EndoPredict® Breast Cancer Prognostic Test October 16, 2020 at 9:05 AM…

SALT LAKE CITY, Aug. 21, 2020 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in molecular diagnostics and…

Publications Demonstrate the Ability of the PRS Component of riskScore® to Accurately Stratify Breast Cancer Risk in Women Both With and…